About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker BNTX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe a…
NCT07111520 · Non-small Cell Lung Cancer
BNT326, Pumitamig
BNTX
BioNTech SE
Phase 1/2Recruiting880Nov 2028Registry ↗
Nov 10, 2026A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used i…
NCT06827236 · Locally Advanced Breast Cancer, Unresectable Breast Carcino…
BNT323, BNT327
BNTX
BioNTech SE
Phase 1/2Recruiting380Aug 2029Registry ↗
Nov 10, 2026A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patien…
NCT06340568 · Endometrial Cancer
BNT323/DB-1303, Doxorubicin
BNTX
BioNTech SE
Phase 3Recruiting480Mar 2028Registry ↗
Nov 10, 2026A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combi…
NCT04534205 · Unresectable Head and Neck Squamous Cell Carcinoma, Metasta…
BNT113, Pembrolizumab
BNTX
BioNTech SE
Phase 2/3Active, not recruiting358Apr 2029Registry ↗
Nov 6, 2026Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cel…
NCT06449209 · Extensive-stage Small-cell Lung Cancer, Small-cell Lung Can…
BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2)
BNTX
BioNTech SE
Phase 2Active, not recruiting110Jun 2027Registry ↗
Nov 2, 2026Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investi…
NCT06712316 · Non-small Cell Lung Cancer
Pumitamig, Pembrolizumab
BNTX
BioNTech SE
Phase 2/3Recruiting1,580Jan 2029Registry ↗
Oct 30, 2026ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Canc…
NCT07173751 · Breast Neoplasms
Pumitamig, Nab-paclitaxel/Paclitaxel
BNTX
BioNTech SE
Phase 3Recruiting558Dec 2029Registry ↗
Oct 28, 2026A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it…
NCT07297212 · Recurrent Glioblastoma
Pumitamig, Bevacizumab
BNTX
BioNTech SE
Phase 2Recruiting75Jan 2028Registry ↗
Oct 23, 2026A First-in-human Clinical Trial to Test if the Investigational Drug BNT3219 is Safe and Potentially…
NCT07893054 · Advanced Solid Tumors
BNT3219
BNTX
BioNTech SE
Phase 1Not yet recruiting207Jul 2029Registry ↗
Oct 22, 2026A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Sa…
NCT05432583 · Genital Herpes Simplex Type 2
BNT163, Placebo
BNTX
BioNTech SE
Phase 1Active, not recruiting318Oct 2026Registry ↗
Oct 21, 2026A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for…
NCT07886684 · Advanced Solid Tumors
BNT3210
BNTX
BioNTech SE
Phase 1/2Not yet recruiting173Oct 2029Registry ↗
Oct 16, 2026A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995 · Metastatic Castration-resistant Prostate Cancer
BNT324, Docetaxel
BNTX
BioNTech SE
Phase 3Recruiting736Feb 2031Registry ↗
Oct 16, 2026A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
NCT07300839 · COVID-19, SARS-COV-2 Infection
BNT162b2 Vaccine, Placebo
BNTX
BioNTech SE
Phase 3Completed5,240Sep 22, 2026Registry ↗
Oct 15, 2026A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for…
NCT07186842 · Advanced Solid Cancers
BNT329, CA19-9-targeting monoclonal antibody
BNTX
BioNTech SE
Phase 1/2Recruiting245May 2030Registry ↗
Oct 14, 2026A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adul…
NCT07698600 · HIV -1 Infection
BNT168, Placebo
BNTX
BioNTech SE
Phase 1Recruiting126Feb 2028Registry ↗
Oct 14, 2026Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Pati…
NCT06712355 · Extensive-stage Small-cell Lung Cancer
Pumitamig, Atezolizumab
BNTX
BioNTech SE
Phase 3Recruiting621Apr 2029Registry ↗
Oct 9, 2026A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Bene…
NCT07070232 · Advanced Solid Tumor
BNT326, Pumitamig
BNTX
BioNTech SE
Phase 1/2Recruiting1,438Mar 2028Registry ↗
Oct 7, 2026A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients W…
NCT04486378 · Colorectal Cancer Stage II, Colorectal Cancer Stage III
RO7198457 intravenous (IV), Observational group (no interve…
BNTX
BioNTech SE
Phase 2Active, not recruiting327Nov 2026Registry ↗
Oct 5, 2026A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and…
NCT06469164 · Bacterial Vaginosis
BNT331, Placebo
BNTX
BioNTech SE
Phase 1Completed102Jul 31, 2025Registry ↗
Sep 28, 2026A Study of COVID-19 Vaccine(s) in Children and Adults
NCT07798648 · COVID-19 Vaccines
BNT162b2, BNT162b2
BNTX
BioNTech SE
Phase 3Recruiting700Apr 21, 2027Registry ↗
Sep 15, 2026Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
NCT06150183 · Advanced Malignant Solid Tumor
BNT314
BNTX
BioNTech SE
Phase 1Active, not recruiting41Aug 18, 2026Registry ↗
Sep 15, 2026A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigatio…
NCT05988203 · Monkeypox
BNT166a
BNTX
BioNTech SE
Phase 1/2Completed96Aug 25, 2025Registry ↗
Sep 9, 2026Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
NCT06750185 · Advanced Solid Tumor
BNT317 DL1, BNT317 DL2
BNTX
BioNTech SE
Phase 1/2Recruiting248Apr 2031Registry ↗
Sep 1, 2026A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults…
NCT07392372 · HIV -1 Infection
BNT351, Placebo
BNTX
BioNTech SE
Phase 1Recruiting67Nov 2026Registry ↗
Aug 28, 2026A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an In…
NCT06069544 · Malaria
BNT165c, BNT165d
BNTX
BioNTech SE
Phase 1/2Completed163May 28, 2025Registry ↗
Aug 26, 2026A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy W…
NCT06892548 · Advanced Lung Cancer
BNT324, BNT327
BNTX
BioNTech SE
Phase 1/2Recruiting594Sep 2028Registry ↗
Aug 19, 2026A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People
NCT06683352 · Influenza,Human, COVID-19
Investigational Influenza Vaccine, COVID-19 Vaccine
BNTX
BioNTech SE
Phase 1/2Completed1,353Jul 15, 2025Registry ↗
Aug 13, 2026Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced…
NCT07455734 · Advanced Solid Tumor Cancer
BNT3214
BNTX
BioNTech SE
Phase 1/2Recruiting533Oct 2030Registry ↗
Aug 11, 2026A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immu…
NCT07379580 · Mpox (Monkeypox), Smallpox
BNT166a, Placebo
BNTX
BioNTech SE
Phase 2Recruiting310Jun 2027Registry ↗
Aug 7, 2026A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
NCT07730450 · COVID-19 Vaccines
BNT162b2 Vaccine, Tdap Vaccine
BNTX
BioNTech SE
Phase 4Recruiting200Aug 20, 2027Registry ↗
Aug 7, 2026A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 1…
NCT07222384 · COVID-19, SARS-COV-2 Infection
BNT162b2 (2025/2026 formulation)
BNTX
BioNTech SE
Phase 3Completed344Jul 24, 2026Registry ↗
Aug 6, 2026A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
NCT05543616 · SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronav…
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram…
BNTX
BioNTech SE
Phase 3Completed4,338Jul 10, 2026Registry ↗
Jul 28, 2026A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works Wh…
NCT07255404 · Pancreatic Ductal Adenocarcinoma (PDAC)
Pumitamig, Nab-paclitaxel
BNTX
BioNTech SE
Phase 2Recruiting105Dec 2027Registry ↗
Jul 22, 2026Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in…
NCT05142189 · Non-Small Cell Lung Cancer
BNT116, Cemiplimab
BNTX
BioNTech SE
Phase 1Recruiting320Feb 2030Registry ↗
Jul 1, 2026A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination Wit…
NCT07079631 · Metastatic Colorectal Cancer
BNT314, Pumitamig
BNTX
BioNTech SE
Phase 1/2Recruiting482Dec 2030Registry ↗
Jun 30, 2026Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When…
NCT06449222 · Locally Advanced Breast Cancer, Triple Negative Breast Canc…
BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2)
BNTX
BioNTech SE
Phase 2Active, not recruiting83Aug 2028Registry ↗
Jun 15, 2026A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Co…
NCT07147348 · Advanced Solid Tumor
BNT3212, Pumitamig
BNTX
BioNTech SE
Phase 1/2Recruiting375Nov 2027Registry ↗
Jun 1, 2026A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 i…
NCT07069309 · COVID-19, SARS-COV-2 Infection
BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)
BNTX
BioNTech SE
Phase 3Completed774May 1, 2026Registry ↗
May 28, 2026Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against…
NCT04816643 · SARS-CoV-2 Infection, COVID-19
Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg
BNTX
BioNTech SE
Phase 3Completed11,837Oct 4, 2023Registry ↗
May 22, 2026Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III…
NCT04813627 · Colorectal Cancer Stage II, Colorectal Cancer Stage III
Regular blood sample collection for ctDNA assessment
BNTX
BioNTech SE
—Completed2,079Apr 23, 2025Registry ↗
Apr 28, 2026A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
NCT05997290 · SARS-CoV-2 Infection, COVID-19
BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1)
BNTX
BioNTech SE
Phase 2/3Completed1,051Mar 13, 2025Registry ↗
Apr 24, 2026Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With…
NCT06841055 · Non-small Cell Lung Cancer
Pumitamig, Docetaxel
BNTX
BioNTech SE
Phase 2Recruiting60Oct 2028Registry ↗
Apr 8, 2026Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
NCT05262530 · Solid Tumor
BNT142
BNTX
BioNTech SE
Phase 1/2Terminated73Dec 22, 2025Registry ↗
Mar 25, 2026Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates…
NCT04368728 · SARS-CoV-2 Infection, COVID-19
BNT162b1, BNT162b2
BNTX
BioNTech SE
Phase 2/3Completed46,969Feb 10, 2023Registry ↗
Mar 20, 2026Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population
NCT04649021 · SARS-CoV-2
BNT162b2, Placebo
BNTX
BioNTech SE
Phase 2Completed960Feb 7, 2021Registry ↗
Mar 18, 2026Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against T…
NCT05547464 · Tuberculosis
BNT164a1, BNT164b1
BNTX
BioNTech SE
Phase 1/2Active, not recruiting497Mar 12, 2026Registry ↗
Mar 13, 2026RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID
NCT02316457 · Breast Cancer (Triple Negative Breast Cancer (TNBC))
IVAC_W_bre1_uID, IVAC_W_bre1_uID/IVAC_M_uID
BNTX
BioNTech SE
Phase 1Completed42May 13, 2020Registry ↗
Mar 12, 2026Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients Wi…
NCT02410733 · Melanoma
Lipo-MERIT
BNTX
BioNTech SE
Phase 1Completed119Jun 20, 2023Registry ↗
Jan 26, 2026A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
NCT06821061 · Influenza, COVID-19 (Coronavirus Disease 2019)
Investigational Influenza Vaccine, Investigational COVID-19…
BNTX
BioNTech SE
Phase 1/2Completed2,650Dec 17, 2025Registry ↗
Jan 13, 2026Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
NCT05541861 · SARS-CoV-2 Infection, COVID-19
BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT1…
BNTX
BioNTech SE
Phase 1Completed383Nov 22, 2024Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:12 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances